Impact of Lung Metastasis versus Metastasis of Bone, Brain, or Liver on Overall Survival and Thyroid Cancer-Specific Survival of Thyroid Cancer Patients: A Population-Based Study

Zhong, Miaochun; Khan, Farhana; He, Xianghong; Cui, Lingfei; Lei, Kefeng; Ge, Minghua

doi:10.3390/cancers14133133

Cited by 7 publications

(6 citation statements)

References 41 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The epidemiology of SLM has not been adequately evaluated in the available literature. In addition, studies to date have focused on one speci c primary cancer site and the impact of SLM on that speci c patient population, but there still have been no studies assessing trends, incidence, and survival across age, sex, ethnicity, grade, tumor size, and N stage groups based on different primary cancer types [22][23][24][25]. Especially, the largest body of literature on lung metastasis has focused on digestive system primary cancer [4; 26-30].…”

Section: Discussionmentioning

confidence: 99%

Incidence, prognostic factors, and a nomogram of lung metastases at diagnosis: a pan-cancer population-based study

Zhao

et al. 2023

Preprint

View full text Add to dashboard Cite

Lung metastasis is common and usually associated with poor outcomes in cancer patients. Currently, the epidemiologic and survival data of synchronous lung metastases (SLM) are lacking. We collected 61,493 patients who were diagnosed with lung metastases at the time of primary cancer diagnosis between 2010 and 2017. The age-adjusted incidence of SLM increased from 9.86/100,000 in 2010 to 12.03/100,000 by 2017 [APC: 3.08; 95% CI: 2.30–3.86]. For adults > 35, digestive system cancer is the most common primary site. For younger patients, the top cancers with SLM were more heterogenous. Survival analysis of SLM patients with different primary tumor types suggested that the median OS was the best for the male genital system malignances and the worst for the digestive system malignances. Furthermore, a nomogram comprising age, race, gender, grade, tumor size, N stage and sites was established to predict the 1-/3-/5-year survival probability of patients with SLM, with the C-indexes of 0.628 (95% CI: 0.622–0.634) for the internal validations and 0.620 (95% CI: 0.610–0.630) for the external validations. In conclusion, the incidence of SLM has continued to increase recent years, and a nomogram based on prognostic analysis could accurately quantify the survival rates of patients with SLM.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence, prognostic factors, and a nomogram of lung metastases at diagnosis: a pan-cancer population-based study

Zhao

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Although DTC generally has a good prognosis, a small subset of patients will develop distant metastasis. Overall, distant disease has been reported to occur in 4-21% of patients [59][60][61][62]. The predominant sites of metastases are pulmonary and osseous.…”

Section: Distant Recurrencementioning

confidence: 99%

“…The predominant sites of metastases are pulmonary and osseous. Less common sites include the liver, brain, skin, ovaries, and adrenal glands [8,59,60]. Bone metastases can bring excessive morbidity and poor quality of life for these patients, while pulmonary metastases are the commonest cause of death due to respiratory failure [63].…”

Section: Distant Recurrencementioning

confidence: 99%

“…They concluded that the most significant factors in predicting the outcome in metastatic DTC are age, extra-thyroidal extension, and distant metastasis. Zhong et al [59] studied the impact of lung metastasis compared with bone, brain, or liver metastasis. Included were various types of thyroid carcinoma identified in a Surveillance, Epidemiology, and End Results (SEER) database of 77,322 patients, in which the lung was the most prevalent site.…”

Section: Distant Recurrencementioning

confidence: 99%

See 1 more Smart Citation

Recurrent Differentiated Thyroid Cancer: The Current Treatment Options

Coca‐Pelaz

Rodrigo

Shah

et al. 2023

Cancers

View full text Add to dashboard Cite

Differentiated thyroid carcinomas (DTC) have an excellent prognosis, but this is sometimes overshadowed by tumor recurrences following initial treatment (approximately 15% of cases during follow-up), due to unrecognized disease extent at initial diagnosis or a more aggressive tumor biology, which are the usual risk factors. The possible sites of recurrence are local, regional, or distant. Local and regional recurrences can usually be successfully managed with surgery and radioiodine therapy, as are some isolated distant recurrences, such as bone metastases. If these treatments are not possible, other therapeutic options such as external beam radiation therapy or systemic treatments should be considered. Major advances in systemic treatments have led to improved progression-free survival in patients previously considered for palliative treatments; among these treatments, the most promising results have been achieved with tyrosine kinase inhibitors (TKI). This review attempts to give a comprehensive overview of the current treatment options suited for recurrences and the new treatments that are available in cases where salvage surgery is not possible or in cases resistant to radioiodine.

show abstract

“…In a recent SEER-based study on 1608 patients treated with RAI therapy, 61.9% had pulmonary metastases; the onset was associated with advanced age, poor differentiation, FTC, lymphatic metastasis, tumor size >10 mm, and extracapsular invasion [ 13 ]. In another SEER-based study, isolated lung metastases implied better OS and disease-specific survival than lung–liver, lung–brain, and lung–other multiple metastases; better survival outcomes were related to age <55 years, surgery to the primary site and to the distant sites [ 14 ].…”

Section: Lung Oligometastasesmentioning

confidence: 99%

Oligometastatic disease from differentiated thyroid cancer: best treatment schemes

Colombo

Ottini

Licitra

2022

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of review Patients with slowly progressive and/or symptomatic oligometastatic radioactive iodine refractory (RAIR) differentiated thyroid carcinomas (DTCs) are candidates to receive locoregional treatment to delay the start of systemic therapy with multikinase inhibitors. Information provided by the recent literature has not been extensively reviewed in previous published works, thus we aim to bridge this gap. Recent findings We present for each metastatic site the different locoregional treatment options, contraindications and potential adverse events. Some techniques can be combined together, whereas others are discouraged in certain situations, requiring a high level of expertise and multidisciplinarity in the treatment algorithm. Summary Different techniques of radiation therapy and interventional radiology allow to control the metastatic spread. However, as no clinical trials are available to compare the treatment schemes in terms of safety and potential impact on the prognosis, the most appropriate option for each patient should be selected within a multidisciplinary decision making, taking into account the clinical conditions and the pattern/rapidity of metastatic disease.

show abstract

Impact of Lung Metastasis versus Metastasis of Bone, Brain, or Liver on Overall Survival and Thyroid Cancer-Specific Survival of Thyroid Cancer Patients: A Population-Based Study

Cited by 7 publications

References 41 publications

Incidence, prognostic factors, and a nomogram of lung metastases at diagnosis: a pan-cancer population-based study

Incidence, prognostic factors, and a nomogram of lung metastases at diagnosis: a pan-cancer population-based study

Recurrent Differentiated Thyroid Cancer: The Current Treatment Options

Oligometastatic disease from differentiated thyroid cancer: best treatment schemes

Contact Info

Product

Resources

About